临床常用抗骨质疏松药物

被引：4

作者：

谭雯 ^{[1
]}

吴晞 ^{[2
]}

机构：

[1] 复旦大学附属华东医院内分泌科

[2] 复旦大学附属华山医院内分泌科

来源：

上海医药 | 2013年 / 34卷 / 09期

关键词：

骨质疏松症; 激素替代疗法; 选择性雌激素受体调节剂; 双膦酸盐类药物; 降钙素; 甲状旁腺激素; 维生素D;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

临床常用的抗骨质疏松药物种类很多,各有不同的特点。本文简述各类抗骨质疏松药物的作用机制、作用特点和不良反应。

引用

收藏

页码：6 / 9

页数：4

相关论文

共 14 条

[1]

Bisphosphonate Therapy for Osteoporosis: Benefits; Risks; and Drug Holiday.[J].Michael McClung;Steven T. Harris;Paul D. Miller;Douglas C. Bauer;K. Shawn Davison;Larry Dian;David A. Hanley;David L. Kendler;Chui Kin Yuen;E. Michael Lewiecki.The American Journal of Medicine.2013, 1

[2]

Osteoporosis treatment in postmenopausal women with pre-existing fracture [J].

Cheng, Ming-Huei ;

Chen, Jung-Fu ;

Fuh, Jong-Ling ;

Lee, Wen-Ling ;

Wang, Peng-Hui .

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2012, 51 (02) :153-166

[3]

Evidence-based assessment of the impact of the WHI on women's health [J].

Burger, H. G. ;

MacLennan, A. H. ;

Huang, K-E. ;

Castelo-Branco, C. .

CLIMACTERIC, 2012, 15 (03) :281-287

[4]

Efficacy and Safety of a Once-Yearly i.v. Infusion of Zoledronic Acid 5 mg Versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study [J].

Orwoll, Eric S. ;

Miller, Paul D. ;

Adachi, Jonathan D. ;

Brown, Jacques ;

Adler, Robert A. ;

Kendler, David ;

Bucci-Rechtweg, Christina ;

Readie, Aimee ;

Mesenbrink, Peter ;

Weinstein, Robert S. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (10) :2239-2250

[5]

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.[J].Tahir Masud.Clinical Interventions in Aging.2009, defa

[6]

Comparison of the Effects of Once-Monthly Versus Once-Daily Risedronate in Postmenopausal Osteoporosis: A Phase II, 6-Month, Multicenter, Randomized, Double-Blind, Active-Controlled, Dose-Ranging Study [J].

Ste-Marie, Louis-Georges ;

Brown, Jacques P. ;

Beary, John F. ;

Matzkin, Ellen ;

Darbie, Lynn M. ;

Burgio, David E. ;

Racewicz, Artur J. .

CLINICAL THERAPEUTICS, 2009, 31 (02) :272-285

[7]

Hormonal replacement therapy (HRT) in postmenopause: A reappraisal [J].

Caufriez, A. .

ANNALES D ENDOCRINOLOGIE, 2007, 68 (04) :241-250

[8]

Prior hormone therapy and breast cancer risk in the Women's Health initiative randomized trial of estrogen plus progestin [J].

Anderson, Garnet L. ;

Chlebowski, Rowan T. ;

Rossouw, Jacques E. ;

Rodabough, Rebecca J. ;

McTiernan, Anne ;

Margolis, Karen L. ;

Aggerwal, Anita ;

Curb, J. David ;

Hendrix, Susan L. ;

Hubbell, F. Allan ;

Khandekar, Jamardan ;

Lane, Dorothy S. ;

Lasser, Norman ;

Lopez, Ana Maria ;

Potter, JoNell ;

Ritenbaugh, Cheryl .

MATURITAS, 2006, 55 (02) :103-115

[9]

Parathyroid Hormone (1–84) and Treatment of Osteoporosis.[J].Sarah P Shrader;Kelly R Ragucci.Annals of Pharmacotherapy.2005, 9

[10]

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene [J].

Duvernoy, CS ;

Kulkarni, PM ;

Dowsett, SA ;

Keech, CA .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (04) :444-452